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Abstract
Background: Epidemiological studies have shown that microalbuminuria is an important risk
factor for arteriosclerosis, coronary heart disease and other vascular diseases in persons with type
2 diabetes. In the present study we examined the prevalence and risk factors for micro- and
macroalbuminuria and examined glycemic control as well as treatment of modifiable cardiovascular
risk factors in persons with known type 2 diabetes in Germany.
Methods: The presented data were derived from the 'KORA Augsburg Diabetes Family Study',
conducted between October 2001 and September 2002. Participants were adults aged 29 years and
older with previously diagnosed type 2 diabetes (n = 581). Microalbuminuria was defined as an
albumin-creatinine ratio of 30 to 300 mg/g, and macroalbuminuria as an albumin-creatinine ratio of
more than 300 mg/g.
Results:  Microalbuminuria was revealed in 27.2% and macroalbuminuria in 9.0% of the 581
included diabetic persons. Multivariable regression analysis identified HBA1c, duration of diabetes,
systolic blood pressure, serum creatinine, smoking and waist circumference as independent risk
factors associated with albuminuria (micro- or macroalbuminuria). Relatively few persons with type
2 diabetes achieved treatment targets of HbA1c < 7% (46.6%), total cholesterol < 200 mg/dl
(44.1%), and LDL cholesterol < 100 mg/dl (16.0%). Optimal HDL cholesterol values (> 45 mg/dl in
men, > 55 mg/dl in women) were found in 55.8%, and blood pressure values < 130 and < 85 mmHg
in 31.3% of the persons
Conclusion:  Albuminuria is common among German persons with known type 2 diabetes.
Despite evidence-based guidelines, only a small proportion of type 2 diabetic persons achieved the
recommended levels of glycemic control and control of cardiovascular risk factors.
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Background
Throughout the world, the number of people developing
type 2 diabetes mellitus is increasing dramatically. At the
present time the disease affecting around 171 million
people worldwide and the World Health Organization
predicts that this number will rise to 366 million by 2030
[1]. Consequently, the number of people developing dia-
betes-related complications will increase. Microalbu-
minuria is a common complication of diabetes and
appears to be a strong predictor of subsequent develop-
ment of overt diabetic nephropathy [2], which is the lead-
ing cause of end-stage renal disease in the western world
[3,4]. Without any intervention, among type 2 diabetic
patients about 20–40% with microalbuminuria progress
to overt nephropathy and finally approximately 20%
develop end stage renal failure [5,6]. However, microalbu-
minuria does not only predict future risk of renal injury
but is also considered to be associated with an increased
risk of cardiovascular events and mortality [7].
Prior studies have shown that the risk factors correlated
with the progression of nephropathy in persons with type
2 diabetes are blood pressure, lipid levels, obesity, ciga-
rette smoking, glycaemic control, and anemia [8,9]. Thus,
studies on diabetes related complications are very impor-
tant to estimate the consequence and burden of diabetes.
The aims of the present study are to determine the preva-
lence of and factors associated with micro- and mac-
roalbuminuria in persons with type 2 diabetes and to
examine the achievement of international guideline tar-
gets with regard to glycaemic control and the manage-
ment of modifiable cardiovascular risk factors.
Methods
Study population
The presented data were derived from the 'Augsburg Dia-
betes Family Study' which was conducted between Octo-
ber 2001 and September 2002. The primary goal of the
study was to enrol families to investigate the role of genes
as well as environmental factors in the development of
type 2 diabetes [10]. Families were ascertained through an
index proband with known type 2 diabetes having at least
one full sib or both parents willing to participate in the
study. All index probands came from the study region of
Augsburg. Altogether 1532 subjects (755 men, 777
women; 614 index probands, 918 full sibs and parents)
aged 20 to 98 years could be examined in the KORA
(Cooperative health research in the region of Augsburg)
study centre. For the present study only index probands
with known type 2 diabetes were included (n = 614). We
excluded from the present analysis 33 subjects with miss-
ing values on any of the considered risk factors. Finally,
the analyses comprised 581 type 2 diabetic subjects (352
men and 229 women) aged 29 to 83 years.
The study was conducted according to the principles
expressed in the Declaration of Helsinki as revised in 2000
and was approved by the ethics committee of the Bavarian
Medical Association. All participants gave their written
informed consent.
Data collection
Baseline information on sociodemographic variables,
smoking habits, physical activity level, medication use,
parental history of diseases, and alcohol consumption
were gathered by trained medical staff (mainly nurses)
during a standardized face to face interview. Individuals
with known type 2 diabetes were asked to report their age
at disease onset. Anthropometric measurements were
made by trained personnel, subjects wearing light indoor
clothing and no shoes. Body weight was measured to the
nearest 0.1 kg, height to the nearest mm, and waist and
hip circumferences to the nearest mm while the proband
was standing. Blood pressure was measured at the right
arm in a sitting position after a fifteen-minute rest using a
validated automatic device (OMRON 705-CP); 3 meas-
urements were taken with 3-minute intervals between the
measurements. For the present analysis, the results of the
second and third measurements were averaged
Laboratory procedures
Total cholesterol was determined by cholesterol-esterase
method (CHOL Flex, Dade-Behring, Germany), HDL cho-
lesterol using the AHDL Flex (Dade-Behring), and LDL
cholesterol was measured by a direct homogeneous
method (GreinerBiochemica, Germany), respectively.
Urinary albumin and creatinine levels were determined in
a random spot urine specimen (Tina-Quant, Roche Diag-
nostics for the measurement of urinary albumin and
KREA Flex, Dade-Behring, for the measurement of urinary
creatinine). Serum creatinine was determined using a
modified Jaffe test (KREA Flex, Dade-Behring), and serum
uric acid was measured using an enzymatic colorimetric
test (URCA Flex, Dade-Behring). HbA1c was determined
by a turbidimetric immunological inhibition assay
(TINIA, Dade-Behring).
Definition of variables
Body mass index (BMI) was calculated as weight in kilo-
grams divided by height in square meters and waist-to-hip
ratio as waist divided by hip circumference. Dyslipidemia
was defined as total cholesterol to HDL cholesterol ratio ≥
5. Education level was categorized into 'low' (< 12 years of
schooling) and 'high' (≥ 12 years of schooling). A regular
smoker was defined as a subject who smoked at least one
cigarette per day. Alcohol intake was classified into the
three categories 0, 0.1–19.9, and 20.0 or more g/day for
women and 0, 0.1–39.9, and 40 or more g/day for men.
Participants were defined as active during leisure time if
they regularly participated in sports in summer and winterBMC Health Services Research 2008, 8:226 http://www.biomedcentral.com/1472-6963/8/226
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and if they were active for at least 1 hour per week in either
season. The abbreviated Modification of Diet in Renal
Disease (MDRD) Study Group equation was used to cal-
culate eGFR: eGFR (mL/min/1.73 m2) = 186.3 × (serum
creatinine-1.154) × (age-0.203) × 0.742 (if female) × 1.212 (if
black) [11]. Microalbuminuria was defined as an albu-
min-creatinine ratio of 30 to 300 mg/g, and macroalbu-
minuria as an albumin-creatinine ratio of more than 300
mg/g.
Self-reported type 2 diabetes was validated by hospital
records or by contacting the proband's treating physician.
Target definitions
To be comparable with previous studies, due to the guide-
lines from the European Society of Hypertension-Euro-
pean Society of Cardiology [12], the American Diabetes
Association [13], and the Joint National Committee VII
[14], the following recommended targets were considered
in the present paper: < 7.0% for HbA1c, < 130/85 mmHg
for blood pressure, < 100 mg/dl for LDL cholesterol, < 200
mg/dl for total cholesterol, < 25 kg/m2 for BMI, and > 45
mg/dl (men) and > 55 mg/dl (women) for HDL choles-
terol.
Statistical analysis
Means or proportions for baseline clinical and laboratory
characteristics were computed for subjects with and with-
out micro- or macroalbuminuria. The Chi2-Test was used
to test the differences in prevalences. The general linear
model was used to compare means (F-Test). Multiple
logistic regression analysis was done using albuminuria
(including micro- and macroalbuminuria) as the depend-
ent variable and age, sex, BMI, waist circumference,
diastolic blood pressure, systolic blood pressure, total
cholesterol values, HbA1c values, duration of diabetes,
serum creatinine, and regular smoking as independent
variables. Significance tests were two tailed and p-values
less than 0.05 are stated as statistically significant. All
analyses were performed using the Statistical Analysis Sys-
tem (Version 9.1, SAS Institute Inc., Cary, NC).
Results
Microalbuminuria was revealed in 158 of 581 diabetic
persons (27.2%) and proteinuria was found in 52 of 581
diabetic persons (9.0%).
Characteristics of the study participants
The clinical and laboratory characteristics of all partici-
pants included in the study and of the subjects with and
without micro- or macroalbuminuria are shown in Table
1. Subjects with microalbuminuria or proteinuria had a
significantly higher WHR, a higher waist circumference,
higher HbA1c values, higher creatinine values, higher
total cholesterol as well as LDL cholesterol values, higher
uric acid levels, and higher systolic and diastolic blood
pressure values than subjects with normoalbuminuria.
Diabetic persons with microalbuminuria or proteinuria
were more frequently of male gender, and the duration of
diabetes was significantly longer compared to nor-
moalbuminuric subjects. The GFR values were signifi-
cantly lower than in those without microalbuminuria or
proteinuria. There were no significant differences with
regard to BMI, regular smoking, physical activity, alcohol
consumption, and history of CVD between subjects with
microalbuminuria or proteinuria and normoalbuminuric
participants.
Risk factors associated with albuminuria
In the multiple logistic regression analysis using albu-
minuria as the dependent variable a number of risk factors
associated with albuminuria could be identified. It was
found that systolic blood pressure, HbA1c, duration of
diabetes, serum creatinine values, regular smoking and
waist circumference were significantly associated with
albuminuria (Table 2).
Antidiabetic and cardiovascular drug treatment
Table 3 presents the antidiabetic treatment as well as the
treatment with antihypertensive/cardiovascular drugs in
the different groups. Normoalbuminuric subjects were
more often treated with oral antidiabetic medication only
(42.1%) in comparison to microalbuminuric (30.4%)
and macroalbuminuric (30.8%) persons. Contrary, sub-
jects with micro- and macroalbuminuria were signifi-
cantly more often treated with insulin only (38.6% and
36.5%, respectively) or insulin in combination with oral
antihyperglycemics (26.0% and 30.8%, respectively) than
normoalbuminuric persons.
In comparison with normoalbuminuric participants, sub-
jects with micro- and macroalbuminuria were signifi-
cantly more frequently treated with diuretics (37.5%,
50.0% and 51.9%, respectively) and beta-blockers
(40.2%, 38.6%, and 57.7%, respectively). For ACE inhib-
itors, AT1 blockers, calcium channel blockers as well as
lipid lowering drugs and antiplatelets there were no statis-
tically significant differences between the three groups
(Table 3).
Glycemic control and treatment of cardiovascular risk 
factors
In this study only a small proportion of persons with type
2 diabetes reached adequate glycemic control as well as
optimal treatment of modifiable cardiovascular risk fac-
tors according to guidelines. HbA1c value was < 7% in
46.6%, total cholesterol was < 200 mg/dl in 44.1%, and
LDL cholesterol was < 100 mg/dl in 16.0% of the partici-
pants. Optimal HDL cholesterol values were found inBMC Health Services Research 2008, 8:226 http://www.biomedcentral.com/1472-6963/8/226
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55.8%, and blood pressure values < 130 and < 85 mmHg
in 31.3% of the persons (Table 4).
Discussion
The present study conducted in a study sample of type 2
diabetic persons recruited from the general population
with median diabetes duration of 7.0 years showed that
microalbuminuria (27.2%) and macroalbuminuria
(9.0%) is common among German persons with known
type 2 diabetes. Logistic regression modeling identified
HBA1c, duration of diabetes, systolic blood pressure,
serum creatinine, smoking and waist circumference as
independent risk factors associated with albuminuria. In
this study neither adequate glycemic control nor optimal
treatment of modifiable cardiovascular risk factors accord-
ing to guidelines was achieved in persons with type 2 dia-
betes.
Because the results of hitherto existing studies on this
issue are based on different population characteristics
(ethnicity, duration of diabetes, age-range, inclusion of
type 1 and type 2 diabetic persons) direct comparisons
with regard to the prevalence of microalbuminuria and
macroalbuminuria between the investigations are diffi-
cult. So far, only a few studies of albuminuria in patients
with type 2 diabetes anywhere in the world were popula-
tion-based [15-18]. In the Third National Health and
Nutrition Examination Survey, the prevalence of albu-
minuria was 34% (28.1% microalbuminuria, 6.1% mac-
roalbuminuria) among persons with previously
diagnosed type1 and type 2 diabetes [17], whereas in a
study from Italy [16] the prevalence of albuminuria was
49.7% in known type 2 diabetic persons (32.1% micro-
albuminuria, 17.6% macroalbuminuria). In a prior Ger-
man study including patients with recently diagnosed
type 2 diabetes 19% exhibited microalbuminuria and
5.2% macroalbuminuria [19]. Furthermore, another
study including diabetic patients treated in primary care
Table 1: Clinical characteristics and laboratory parameters in all study participants and diabetic participants with normoalbuminuria, 
microalbuminuria, and macroalbuminuria
Characteristics All study participants Normo-albuminuric Micro-albuminuric Macro-albuminuric P***
N N = 581 n = 371 n = 158 n = 52
Age (years) 61.0 (9.5) 60.3 (9.9) 62.3 (8.8) 61.7 (8.5) 0.0859
Men (%) 60.6 56.3 63.3 82.7 0.0009
Duration of diabetes (years) 9.5 (8.3) 8.3 (7.5) 11.3 (9.1) 13.2 (9.4) < 0.0001
BMI (kg/m2) 30.8 (5.3) 30.6 (5.2) 31.0 (5.3) 31.1 (6.4) 0.6640
Waist-hip ratio 0.95 (0.08) 0.94 (0.07) 0.96 (0.08) 0.97 (0.08) 0.0005
Waist circumference (cm) 105.2 (12.8) 104.1 (12.4) 106.8 (13.4) 108.5 (13.0) 0.0129
Systolic blood pressure (mmHg) 140.0 (21.7) 135.2 (19.4) 145.6 (21.1) 157.7 (26.0) < 0.0001
Diastolic blood pressure (mmHg) 80.8 (10.9) 79.9 (10.5) 82.0 (11.4) 83.7 (11.5) 0.0158
Regular smoker (%) 13.9 12.4 15.2 21.2 0.2023
Physical inactivity (%) 57.3 56.6 57.0 63.5 0.6415
Alcohol intake 0 g/day (%) 41.3 40.7 39.9 50.0 0.4380
0.1–39.9 (men) 0.1–19.9 (women) 
(%)
45.3 46.1 47.5 32.7
≥ 40 g/day (men) ≥ 20 g/day 
(women) (%)
13.4 13.2 12.7 17.3
History of cardiovascular events (%) 27.7 25.3 29.8 38.5 0.1124
HbA1c (%) 7.3 (1.4) 7.1 (1.2) 7.5 (1.6) 8.1 (1.8) < 0.0001
Serum creatinine (mg/dl)* 1.04 (1.33) 0.99 (1.24) 1.09 (1.43) 1.26 (1.47) < 0.0001
GFR (ml/min per 1.73 m2)** 71.6 (18.9) 73.7 (16.9) 69.5 (21.0) 63.2 (22.2) 0.0002
Total cholesterol (mg/dl) 207.4 (42.2) 203.7 (39.6) 212.5 (44.7) 218.2 (49.9) 0.0139
LDL cholesterol (mg/dl) 129.0 (30.7) 126.3 (28.2) 132.7 (32.8) 137.2 (37.9) 0.0109
HDL cholesterol (mg/dl) 50.0 (14.8) 50.5 (13.9) 49.3 (17.1) 48.4 (13.5) 0.5150
Serum uric acid (mg/dl) 5.7 (1.6) 5.5 (1.4) 6.0 (1.7) 6.3 (1.9) < 0.0001
Data are means (± SD) unless otherwise indicated. Cardiovascular events include acute myocardial infarction or stroke
* geometric mean
**estimated from the MDRD equation
***p-value for differences between type 2 diabetes subjects with normo-, micro- and macroalbuminuria
Table 2: Multiple logistic regression analysis using albuminuria as 
a dependent variable
Variable OR (95% CI)
HbA1c (%) 1.25 (1.09 – 1.44)
Duration of diabetes (years) 1.05 (1.02 – 1.07)
Systolic blood pressure (mmHg) 1.03 (1.02 – 1.04)
Serum creatinine (mg/dl)* 4.27 (2.09 – 8.70)
Regular smoking 2.07 (1.20 – 3.57)
Waist circumference (cm) 1.02 (1.01 – 1.04)
*Serum creatinine log-transformedBMC Health Services Research 2008, 8:226 http://www.biomedcentral.com/1472-6963/8/226
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reported a prevalence of microalbuminuria (macroalbu-
minuria) of 17.2% (10.8%) in Type 2 diabetes [20].
Although the present study was not population-represent-
ative the proportion of microalbuminuria and mac-
roalbuminuria is similar to that reported in other studies
and gives therefore a realistic estimation of the prevalence
of albuminuria among type 2 diabetic persons in Ger-
many [16-20].
In the present study HbA1c level, duration of diabetes,
systolic blood pressure, serum creatinine, regular smok-
ing, and waist circumference were significantly associated
with albuminuria. This finding is in agreement with other
studies, which also reported that diabetes duration
[18,21], and hypertension [18,21] are important factors
in the development of albuminuria. So far, only a few
studies have found that smoking is a risk factor for albu-
minuria among persons with type 2 diabetes [22]. In this
study, persons who smoked regularly were twice as likely
to have albuminuria compared with those who did not.
Furthermore, in agreement with other studies, in our
study HbA1c levels were also associated with the develop-
ment of albuminuria [23]. While other studies mostly
identified BMI as risk factor for albuminuria [18], in our
study waist circumference was more strongly associated
with albuminuria than BMI.
In the present study persons with micro- or macroalbu-
minuria were more frequently treated with insulin alone
or with insulin in combination with oral antidiabetic
drugs in comparison to normoalbuminuric type 2 diabe-
tes mellitus persons. This result is plausible and in agree-
ment with findings from other studies [24], because
intensification of treatment reflects the natural progres-
sion of the disease; due to long-standing disease compli-
cations and comorbidities occur which require insulin
therapy to manage type 2 diabetes persons.
Results from randomized clinical trials demonstrated that
control of glucose levels as well as blood pressure, and
cholesterol levels can delay or prevent the macrovascular
and microvascular complications of diabetes [25-28].
Despite the guidelines, developed on the basis of such
data, in the present study only a small proportion of per-
sons with type 2 diabetes achieved the recommended lev-
els of control. This is in accordance with results from other
studies [24,29-31].
The Augsburg Diabetes Family Study has several limita-
tions that need to be considered. The present study was
cross-sectional in design, thus, longitudinal trends in the
management of diabetes and modifiable risk factors could
not be taken into account. Furthermore, a single random
spot urine sample was used to determine albuminuria.
Unfortunately, in the present study no data on the repro-
ducibility of the urinary albumin excretion measurement
was available. Although the study participants were
recruited from the general population the present study
was not population representative in design. Furthermore,
selection bias cannot be excluded, as the study population
could be expected to include an above average proportion
Table 3: Antidiabetic medication in diabetic participants with normoalbuminuria, microalbuminuria, and macroalbuminuria
Medication Normoalbuminuric Microalbuminuric Macroalbuminuric P
N n = 371 n = 158 n = 52
Antidiabetic treatment
Oral antidiabetic medication only (%) 42.1 30.4 30.8 0.0062
Insulin only (%) 26.7 38.6 36.5
Oral antidiabetic medication in combination with insulin (%) 20.2 26.0 30.8
No antidiabetic drug 11.1 5.1 1.9
Antihypertensive/Cardiovascular medication
Beta blockers (%) 40.2 38.6 57.7 0.0401
ACE inhibitors (%) 44.7 46.2 48.1 0.8801
Diuretic use (%) 37.5 50.0 51.9 0.0092
AT1 blockers (%) 8.9 9.5 15.4 0.3311
Calcium channels blockers (%) 17.8 22.8 23.1 0.3353
Lipid lowering drugs (%) 37.2 36.7 42.3 0.7523
Antiplatelet drugs (%) 44.7 45.6 44.2 0.9794
Table 4: The percentage of type 2 diabetic participants who 
achieved optimal treatment goals for modifiable risk factors
Risk factors %
HbA1c < 7% 46.6
Total cholesterol < 200 mg/dl 44.1
HDL cholesterol > 45 mg/dl (men), > 55 mg/dl (women) 55.8
LDL cholesterol < 100 mg/dl 16.0
Blood pressure < 130 and 85 mmHg 31.3
BMI < 25 kg/m2 9.8
Current non-smoker 86.1BMC Health Services Research 2008, 8:226 http://www.biomedcentral.com/1472-6963/8/226
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of motivated persons with type 2 diabetes. This selection
may have underestimated the reported prevalences of
albuminuria and shortcomings in disease management.
However, the present study has also a number of
strengths. Contrary to some prior studies, which were con-
ducted in selected, e.g. clinic-based, patient groups
[21,31] the present study was based on study participants
recruited from the general population. Also, studies on
this issue based on a well characterized study population
as the present one including a great number of pheno-
types, risk factors and comorbidities are scarce. Further-
more, contrary to other papers on this subject [17,18] the
present paper additionally contains data on antidiabetic
and cardiovascular treatment. In addition, this study is
one of relatively few from Germany dealing with micro-
albuminuria. Thus, since type 2 diabetes is one of the
most common health problems in primary care, we
believe that our results can be applied to improve the
management of cardiovascular risk factors, glycemic con-
trol and microalbuminuria in patients with type 2 diabe-
tes.
Conclusion
In conclusion, the present study could show that the prev-
alences of microalbuminuria and macroalbuminuria in a
German sample of persons with type 2 diabetes were com-
parable to those shown in other studies. Despite the high
risk of cardiovascular events and mortality among type 2
diabetic persons, in our study control of diabetes and risk
factors was not optimal. Thus, glycemic control and man-
agement of cardiovascular risk factors should be intensi-
fied to effectively reduce the risk of micro- and
macrovascular complications in diabetic persons.
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